Literature DB >> 9703936

Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis.

B Slesak1, A Harlozinska, I Porebska, T Bojarowski, J Lapinska, M Rzeszutko, A Wojnar.   

Abstract

The expression and coexpression of EGFR, c-erbB-2 and c-erbB-3 in 21 gastric cancers and 20 chronic gastritis was examined using immunohistochemistry on fresh frozen tissues considering clinicopathological variables. Generally, gastric cancer patients showed a higher incidence of EGFR, c-erbB-2 and d-erbB-3 overexpression than the group with chronic gastritis (81% and 43%; 38% and 45%; 35% and 20%, respectively), however, statistically significant differences were found only for EGFR expression (p = 0.01). No association between immunoreactivity of all growth factor receptors and the histopathological structure of gastric cancer was observed. EGFR and c-erbB-3 proteins were detected more frequently in patients with III/IV than in I/II of TNM stages, while c-erbB-2 overexpression was higher in I/II vs. III/IV stages. In chronic gastritis with intestinal metaplasia and or coexisting carcinoma lesions, a higher frequency of the expression of studied proteins was observed in comparison with chronic gastritis without those alternations; however, these differences were statistically insignificant. The percentage of positive cases with coexpression of two proteins was comparable in gastric cancer and chronic gastritis (33% and 35%) but the simultaneous expression of all three receptors was evident only in gastric cancer (19%). Our results indicate that at least one or two members of EGFR related receptors could appear in the early stages of gastric tumorigenesis. The enhancement of c-erbB-2 and c-erbB-3 reactivity seems to cooperate with EGFR activation in the gastric cancer development. Our results indicate the promotional rather than direct transformational role for EGFR supergene family in gastric carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703936

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

1.  Gastrokine 1 inhibits gastrin-induced cell proliferation.

Authors:  Olga Kim; Jung Hwan Yoon; Won Suk Choi; Hassan Ashktorab; Duane T Smoot; Suk Woo Nam; Jung Young Lee; Won Sang Park
Journal:  Gastric Cancer       Date:  2015-03-10       Impact factor: 7.370

2.  HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma.

Authors:  Hee Jin Lee; Joon-Yong Chung; Stephen M Hewitt; Eunsil Yu; Seung-Mo Hong
Journal:  Virchows Arch       Date:  2012-10-02       Impact factor: 4.064

3.  A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

Authors:  Chul Kim; Jae-Lyun Lee; Min-Hee Ryu; Heung Moon Chang; Tae Won Kim; Ho Young Lim; Hye Jin Kang; Young Suk Park; Baek-Yeol Ryoo; Yoon-Koo Kang
Journal:  Invest New Drugs       Date:  2009-12-09       Impact factor: 3.850

4.  DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.

Authors:  Shoumin Zhu; Abbes Belkhiri; Wael El-Rifai
Journal:  Gastroenterology       Date:  2011-07-07       Impact factor: 22.682

5.  Effects of epidermal growth factor on the growth of human gastric cancer cell and the implanted tumor of nude mice.

Authors:  Lu Xia; Yao-Zong Yuan; Chun-Di Xu; Yong-Pin Zhang; Ming-Ming Qiao; Jia-Xu Xu
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

6.  Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients.

Authors:  N-Lale Satiroglu-Tufan; Ferda Bir; Nese Calli-Demirkan
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

7.  Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers.

Authors:  D G Power; D H Ilson
Journal:  Ther Adv Med Oncol       Date:  2009-11       Impact factor: 8.168

8.  Effect of Helicobacter pylori infection on epidermal growth factor receptor (EGFR) expression and cell proliferation of gastric epithelial mucosa: correlation to macroscopic and microscopic diagnosis.

Authors:  Agnes Ruzsovics; Zsuzsa Unger; Bela Molnar; Laszlo Pronai; Zsolt Tulassay
Journal:  Int J Exp Pathol       Date:  2002-10       Impact factor: 1.925

9.  Expression of EGF-receptor related protein (ERRP) decreases in gastric mucosa during aging and carcinogenesis.

Authors:  Adhip P N Majumdar; Jianhua Du; James S Hatfield; Edi Levi; Volkan Adsay; Eva M Schmelz; Kiran K Nagothu; Richard Jaszewski; Omer Kucuk; Fazlul H Sarkar
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

Review 10.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.